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 Cystic Fibrosis (CF) is a genetic disease 
characterised by a deficit in epithelial Cl
- 
secretion leading to airway dehydration and a 
reduced Airway Surface Liquid (ASL) height. 
The endogenous lipoxin LXA4 is a member of 
the newly identified eicosanoids playing a key 
role in ending the inflammatory process. Levels 
of LXA4 are decreased in the airways of 
patients with CF.  We have previously shown 
that in normal human bronchial epithelial cells, 
LXA4 produced a rapid and transient 
intracellular Ca
2+
 increase. We have 
investigated here, the effect of LXA4 on Cl
-
 
secretion and the functional consequences on 
ASL height in bronchial epithelial cells 
obtained from CF and non-CF  patient biopsies 
and in bronchial epithelial cell lines. We found 
that LXA4 stimulated a rapid intracellular Ca
2+
 
increase in all of the different CF bronchial 
epithelial cells tested.  In non-CF and CF 
bronchial epithelia, LXA4 stimulated whole-cell 
Cl
-
 currents which were inhibited by NPPB 
(calcium-activated Cl
-
 channel inhibitor), 
BAPTA-AM (chelator of intracellular Ca
2+
) but 
not by CFTRinh-172 (CFTR inhibitor). We 
found, using confocal imaging, that LXA4 
increased the ASL height in non-CF and in CF 
airway bronchial epithelia. The LXA4 effect on 
ASL height was sensitive to bumetanide an 
inhibitor of transepithelial Cl
-
 secretion. The 
effects of LXA4 on intracellular Ca
2+
, whole-cell 
Cl
-
 currents, conductances and ASL height 
were inhibited by Boc-2 the antagonist of the 
ALX/FPR2 receptor.  Our results provide, for 
the first time, evidence for a novel role of LXA4 
in the stimulation of Ca
2+
 signalling, Ca
2+
-
activated Cl
-
 secretion and ASL height  in non-
CF and CF bronchial epithelia. 
 
We have investigated the role of lipoxin A4 
on cystic fibrosis airway epithelium secretory 
function. Cystic fibrosis is caused by the mutation 
of the gene coding for the Cystic Fibrosis 
Transmembrane conductance Regulator (CFTR), a 
cyclic AMP-dependent Cl
-
 channel. The major 
clinical features of CF are chronic pulmonary 
disease, exocrine pancreatic insufficiency and 
male infertility (1, 2). The lung disease is the main 
cause of morbidity and mortality in CF. The 
airway epithelium of patients with CF fails to 
transport Cl
-
 and water, resulting in a reduced ASL 
height and impaired mucociliary clearance. The 
hyper-absorption of Na
+
 observed in the CF 
bronchial epithelium may further exacerbate the 
dehydration of the ASL. It is generally accepted 
that the dehydration of the airway lumen favours 
chronic infection and inflammation leading to 
progressive destruction of the lung (3). 
Identification of agents, particularly natural 
endogenous biologicals, which stimulate 
alternative non-CFTR Cl
-
 secretory pathways and 
promote ASL hydration and optimal ASL height 
recovery are likely to be of therapeutic benefit in 
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improving mucociliary clearance in patients with 
CF. 
The levels of LXA4 have been reported to be 
decreased in the airways of patients with CF (4). 
Lipoxins are bioactive lipids derived from omega-
6 polyunsaturated fatty acids playing important 
roles in various biological functions (5). The 
endogenous lipoxin A4 (LXA4: 5S,6R,15S-
trihydroxy-7,9,13-trans-11-eicosatetraenoic acid) 
is produced at inflammatory sites from the 
interaction of lipoxygenase activities of several 
cell types including leukocytes, platelets and 
epithelial cells. This lipid mediator is one member 
of the newly identified molecules playing a role in 
ending/resolving the inflammatory process by 
modulating neutrophilic inflammation, clearing 
apoptotic PMN and inhibiting the production of 
pro-inflammatory cytokines (6). The deficit in 
LXA4 in CF could be a contributing factor in 
chronic airway inflammation which characterises 
these patients. 
Very little is known about the role of LXA4 
in the lung beyond its anti-inflammatory effects. 
We have previously shown that normal human 
bronchial epithelial cells are a biological target for 
LXA4. The receptor for LXA4 (ALX/FPR2) is 
expressed in the bronchial epithelial cell line 
16HBE14o- and LXA4 stimulates an intracellular 
Ca
2+
 mobilisation in these cells (7). Intracellular 
Ca
2+
 is a major regulator of Cl
-
 transport and the 
stimulation of epithelial Cl
-
 secretion would be of 
major therapeutic benefit in CF to restore efficient 
airway clearance, therefore we have investigated 
the effect of LXA4 on epithelial Cl
-
 secretion and 
its functional consequences on ASL height using 
bronchial epithelial cells obtained from CF and 
non-CF patient biopsies and in a variety of 
bronchial epithelial cell lines commonly used as 
models for CF ion transport and immunological 
studies.  
 
 
Experimental procedures 
 
Cell Culture. For the primary culture of  
human bronchial epithelium, the cells were 
obtained from endobronchial biopsies in non-CF 
and CF patients (Local Ethics Committee 
approval and patient consent). The bronchial 
epithelial cell samples were taken from a normal 
area of bronchi in 4 patients with a normal lung 
function and from 3 CF patients homozygote for 
the Phe508del mutation. Bronchial epithelium 
biopsies were washed and incubated for two hours 
at room temperature with 250 µg/ml amphotericin 
B in Phosphate Buffer Saline (PBS) without 
calcium and magnesium. After centrifugation, the 
explants were collected and re-suspended in 500 
µl of Bronchial Epithelium Basal Medium 
(BEBM, Clonetics, BioWhittaker, San Diego, 
USA) supplemented with 0.5µg/ml human 
recombinant epidermal growth factor, 7.5 mg/ml 
bovine pituitary extract, 0.5 mg/ml epinephrine, 
10 mg/ml transferrin, 5 mg/ml insulin, 0.1 µg/ml 
retinoic acid, 6.5 µg/ml triiodothyronine,  and 
50 mg/ml gentamicin (BD, Erembodegem, 
Belgium) and 250 µg/ml amphotericin B (BD, 
Erembodegem, Belgium). The explants were 
plated in a 24 well plate (Nunc, Roskilde, 
Denmark) previously coated with a 
fibronectin/collagen solution and incubated at 
37ºC in a humidified 5% CO2 atmosphere. Twenty 
four hours after seeding, the volume of media was 
adjusted to 400µl. The cells were cultured under 
these conditions for six to nine days (confluence 
close to 70 %) before splitting. Fibroblasts were 
removed by 1 minute treatment with trypsin 
EDTA (Gibco, Invitrogen, Paisley, UK). Epithelial 
cells were then trypsinised and re-suspended after 
centrifugation, in supplemented BEBM. The cells 
were seeded at 2500-4000 cells/cm² in flasks (BD, 
Erembodegem, Belgium).  
NuLi-1, CuFi-1, CuFi-3, and CuFi-4 cells 
were kindly donated by Prof Zabner,University of 
Iowa, USA.  The NuLi-1 cell line was derived 
from human airway epithelium of normal 
genotype, whereas CuFi-1, Cufi-3 and CuFi-4 cell 
lines were derived from CF patients with 
Δ508/Δ508, R553X /Δ508, and  G551D/Δ508 
genotypes respectively. The cell lines were 
transformed with a RT component of telomerase 
and human papillomavirus type 16 E6 and E7 
genes (8). Cells were initially grown to 
confluency in flasks using BEBM with EGF, 
hydrocortisone, bovine pituitary extract, 
transferin, bovine insulin, triiodothyronine, 
epinephrine, retinoic acid, penicillin-streptomycin 
(0.025 µg/ml), gentamicin (0.05 ng/ml), and 
amphotericin (25 µg/ml). 
Airway epithelial cells were plated at 2 x 10
6
 
cells/cm
2
 on Millicell hanging cell culture inserts 
(Millipore, Billerica, USA) for ASL height 
measurements. All inserts were pre-coated with 
collagen type VI and grown in BEGM medium 
until confluence was achieved.  
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Once cell confluence was confirmed under 
visual inspection, the medium was switched to 
DMEM/F-12 (Invitrogen, Auckland, New 
Zealand) to aid cell differentiation. This medium 
was supplemented with Ultroser G (2%, Pall 
Biospera, Cergy-Saint-Christophe, France), which 
enhances ion transport (8), and penicillin-
streptomycin (0.025 µg/ml), gentamicin (0.05 
ng/ml), and amphotericin (25 µg/ml). Medium at 
the apical aspect was aspirated every 3-4 days 
until the establishment of an air-liquid interface. 
The basolateral culture medium was replaced 
every 2-3 days.  After 4-6 weeks growth, the cells 
formed a polarised confluent monolayer with a 
high transepithelial electrical resistance (TER) of 
> 700 Ω/cm2. 
 
Intracellular calcium imaging.  Intracellular 
Ca
2+
 was measured by epifluorescence 
microscopy as previously described (9). The 
human airway epithelial cells were cultured on 
fibronectin-collagen coated (for primary culture 
cells) and on collagen VI coated (for NuLi-1 and 
CuFi-1 cells) glass bottom dishes (WPI, 
Stevenage, UK) for 6 days until 70% of 
confluence was reached. Cells were loaded with 5 
µM of the Ca
2+
 -sensitive fluorescent probe fura-
2-acetoxy-methyl ester (fura 2-AM, Invitrogen, 
Auckland, New Zealand) for 30 min, in the dark, 
at room temperature (22°C) and were then washed 
twice in HEPES-buffered Krebs-Henseleit 
solution (140 mM NaCl, 5 mM KCl, 2 mM 
CaCl2, 1 mM MgCl2, 10 mM HEPES, pH 7.4, 
280-290 mOsmol). The glass bottom dishes 
covered with the fura 2-AM loaded epithelial cell 
monolayer were mounted on the stage of an 
inverted microscope equipped for epi-
fluorescence (TE-300, Nikon, Badhoeve Dorp, 
Netherlands). Intracellular Ca
2+
 imaging was 
performed using the Metafluor Imaging System 
(Universal Imaging Corporation). The cell 
preparation was excited alternatively with 
monochromatic light at 340 and 380 nm using an 
Optoscan monochromator (Cairn Research Ltd, 
Kent, UK). The emission fluorescence produced 
after fura 2-AM excitation was filtered at 512nm. 
The emitted light image was detected using a 
Photometrics CoolSNAP-fx video camera (Roper 
Scientific, Evry, France) coupled to the 
microscope. The fluorescence obtained at each 
excitation wavelength (F340 and F380) depended 
upon the level of Ca
2+
 binding to fura 2-AM. The 
results are given as ratiometric data (F340/F380), 
or as amplitude of variation compared to the basal 
ratio level (F340/F380).  
 
Whole-cell patch-clamp recording. Freshly 
isolated epithelial cells obtained from 4 non-CF 
patients and from 3 CF patients (genotype:  
ΔF508/ΔF508) and from the NuLi-1 and CuFi-3 
cell lines were used for patch-clamp experiments. 
The CuFi-1 cells were not used for patch-clamp 
experiments since we could not reach a Giga ohm 
seal with these cells. Cells were patch-clamped at 
room temperature (25°C) on an inverted 
microscope (TE-300, Nikon, Badhoeve Dorp, 
Netherlands). Patch-pipettes were prepared from 
soda glass (Vitrex, Modulhom, Herlev, Denmark), 
pulled on a programmable puller (P80/PC, Sutter 
Instrument Company, USA). The whole-cell 
configuration was obtained from cell-attached 
mode after breaking the patch membrane by 
applying a brief negative pressure in the patch 
pipette. Whole-cell currents were amplified 
(Axopatch 200B, Axon instrument, CA) and 
digitized using a 16-bit data converter (Digidata 
1322A, Axon instrument, CA) following  low pass 
filtering at 5Khz and sampled in real-time. Whole-
cell current voltage (IV) relationships were 
analysed using Clampfit software (Axon 
instrument, CA).  
The patch pipette was filled with a “high K+ 
solution” at pH=7.2, 290mosm: 110mM K-
gluconate, 20mM NaCl, 1.2mM KH2PO4, 
3.46mM, 3mM KH2PO4, 5mM EGTA, 6mM 
HEPES, 2.78mM CaCl2, pH= 7.2 adjusted with 
KOH. The bathing solution had the following 
composition: 140mM NaCl, 5mM KCl, 6mM 
Hepes, 2mM CaCl2, 1.2mM KH2PO4, 1.2mM 
MgSO4 and pH= 7.4. The Nernst potentials 
between the patch pipette and bath for K
+
 and for 
Cl
-
 were -77mV and -39mV, respectively. The 
access resistance (Ra) was determined by fitting 
the current transients produced by a 5mV voltage 
pulse with a single exponential. The measured Ra 
was 5.43±0.08Ω (n=40).  
 
Airway Surface Liquid (ASL) height 
measurements. ASL height was measured using a 
protocol adapted from Tarran et al. (10), using 
live-cell confocal fluorescence microscopy. To 
label the ASL, 8µl PBS containing 1 mg/ml Texas 
red®-dextran (10kD; Invitrogen, Auckland, New 
Zealand) was added to the apical surface of the 
well-differentiated airway epithelium. The 
epithelial cells were stained using Calcein-AM 
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(5μM, Invitrogen, Auckland, New Zealand) 
dissolved in medium culture for 30 minutes and 
introduced to the basolateral compartment of the 
insert. The Fluorinet™ electronic fluid 
Perfluorocarbon-72 (FC-72, 3M, St Paul, USA) 
was added to the apical compartment of the insert 
at a volume of 0.5ml. Perfluorocarbon-72 is 
immiscible with the ASL and was used to prevent 
ASL evaporation on transferring the inserts from 
the incubator to the microscope stage and during 
the confocal scanning experiments. Epithelia were 
Z-scanned using a Zeiss LSM 510 Meta using a 
40X objective. To evaluate the average ASL 
height, for each preparation, 9 separate regions of 
interest were determined within the microscope 
field and were XZ scanned. Images were analysed 
using the Zeiss LSM Image analyser software 
(Carl Zeiss Microlmaging GmbH, Germany). 
Drugs. The lipoxin LXA4 was purchased 
from Calbiochem. Aliquots of LXA4 solution 
(100μM) in ethanol were stored at -80 °C to avoid 
degradation of the molecule. The peptide Boc-
Phe-Leu-Phe-Leu-Phe (Boc-2) (Phoenyx 
pharmaceutical, Belmont, USA) was used as 
specific inhibitor of the ALX/FPR2 receptor (11). 
For these latter experiments, cells were pre-
incubated with 10
-5
M  Boc-2 for 24 hours at 37°C. 
BAPTA-AM (10μM, Molecular probes, Leiden, 
Netherlands) was used to chelate intracellular Ca
2+ 
(12). The 5-Nitro-2-(3-phenylpropylamino) 
benzoic acid (NPPB, Sigma, USA) used at 1μM is 
an inhibitor of Ca
2+
-activated Cl
-
 channels (13). 
CFTRinh-172 an antagonist of the CFTR channel 
and bumetanide an inhibitor of the NKCC1 co-
transporter were supplied by Sigma (14). 
 
Data Analysis. The intracellular Ca
2+
 
variations were measured as the difference 
between the mean F340/F380 ratio during the 2 
min prior to exposure to LXA4 and the ratio 
measured at the peak of the Ca
2+
 response and 2 
and 5 min after the peak. In each experiment, the 
mean ratio was obtained from all cells in the 
microscopic field. In whole-cell patch-clamp 
experiments, conductances were determined by 
linear regression of the current-voltage 
relationship obtained in n cells. For the ASL 
height measurements, three confocal image 
acquisitions were performed on each epithelial 
cell monolayer and nine regions of interest were 
analysed in the acquisition field using the LSM 
image browser (Zeiss). Values were loaded in an 
Excel spreadsheet and averaged. Mean value were 
obtained from n independent experiments. The 
experiments were repeated under the same 
conditions on a minimum of three different cell 
passages. Data are presented as the mean ± S.E.M. 
of n experiments. Measures of statistical 
significance were obtained using the Student's t 
test for paired data. A p value <0.05 was deemed 
to be significant. All statistical operations were 
performed using Excel software (Microsoft). 
 
 
 
RESULTS 
 LXA4 effects on intracellular Ca
2+
 in 
normal and CF bronchial epithelial cells. LXA4 
induced a rapid increase of intracellular Ca
2+
 in all 
human airway epithelial cell types tested. There 
was no significant difference in the maximum 
increase induced by LXA4 (100nM) between non-
CF and CF bronchial epithelial cell lines and 
between non-CF and CF epithelial primary 
cultures, although the absolute peak values were 
higher in the cell lines than in primary cultures. 
However, as shown on figure 1A and 1B, the 
kinetics of the Ca
2+
 responses were not identical 
from one cell type to another. In non-CF bronchial 
epithelial cells (Nuli-1 cell line and NHBE 
primary cultures), the intracellular Ca
2+
 rise 
induced by LXA4 was fast and transient with a 
Ca
2+
 recovery to basal values within 2 to 5 min. In 
contrast, in CF bronchial epithelial cells (CuFi cell 
lines and CFBE primary cultures), LXA4 induced 
a slower Ca
2+
 increase and a delayed (or absent) 
recovery toward basal values (Figure 1B). Thus 
the total amount of Ca
2+
 mobilised in the cytosol 
upon LXA4 exposure was higher in CF than in 
non-CF bronchial epithelial cells.  
 In order to investigate the origin of the 
calcium signal induced by LXA4, we tested the 
effect of LXA4 on intracellular Ca
2+
 in the absence 
of extracellular Ca
2+
 in normal and CF airway 
epithelial cells. The results presented in  figure 1A  
showed that in Nuli-1 cells bathed in external 
Ca
2+
-free solution (grey dotted line), the response 
to LXA4 was not different from the response 
obtained under control conditions (plain line). In 
Nuli-1 cells, there was no significant difference in 
the maximum Ca
2+
  increase obtained after LXA4 
exposure with or without external Ca
2+
 
(F340/F380 : control 8.49±0.48 and external Ca
2+
-
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free 8.57±0.32) and in the value measured 2 min 
after the peak (5.22±0.43 in control condition and 
5.89±0.36 in external Ca
2+
-free). These results 
indicate that in normal airway epithelial cells, 
LXA4 generates a calcium signal mainly due to 
the release of Ca
2+
 from intracellular stores rather 
than Ca
2+
 entry.  As shown figure 1A ,  there was 
no difference in the maximum Ca
2+
  increase in 
CF CuFi-3 cells obtained after LXA4 exposure 
with or without external Ca
2+
 (F340/F380: control 
8.76±0.55 and external Ca
2+
-free: 8.99±0.49). 
However, in external Ca
2+
-free medium, the 
calcium response in CuFi-3 cells to LXA4 was 
more transient with a rapid recovery to basal 
values. The F340/F380  values obtained 2 min 
after the peak Ca
2+
 response were 7.17±0.43 in 
control conditions and 2.29±0.46 in an external 
Ca
2+
-free solution. Taken together, these results 
suggest that, in CF airway epithelia, in addition to 
the Ca
2+
 mobilisation from intracellular stores, 
LXA4 also stimulates Ca
2+
 entry and this response 
is absent in non-CF bronchial epithelial cells 
(figure 1A). 
 
Role of the ALX/FPR2 receptor in the 
calcium response to LXA4. The role of the 
ALX /FPR2 receptor in the Ca
2+
 response to 
LXA4 was investigated using the specific 
inhibitor, Boc-2, in NuLi-1 and CuFi-3 cells 
(figure 2). The effect of LXA4 (100nM) on 
intracellular Ca
2+
 was completely abolished after 
treatment with Boc-2 (10μM) (figure 2A and 2B). 
However, ATP (100μM), a known stimulator of 
intracellular Ca
2+
 mobilisation via purinergic 
receptor stimulation, produced a Ca
2+
 signal in 
cells treated with Boc-2 (figure 2A). These results 
indicate the involvement of the ALX/FPR2 
receptor in the Ca
2+
 signalling response to LXA4. 
LXA4 effects on whole-cell currents in non-
CF and CF bronchial epithelial cells. The 
current-voltage relationship obtained from whole-
cell patch-clamp recordings in non-CF (NHBE) 
and CF (CFBE) primary cultures of human 
bronchial epithelial cells. The time-dependence 
and dose-dependence of the LXA4 effects on 
whole cell current and conductance are presented 
in figures 3 and 4, respectively. Under control 
conditions, the whole-cell currents were 
outwardly rectified in non-CF (gout= 
612.2±165.2pS and gin=227.7±99.3pS, n=16) and 
CF (gout=855.4±192.9pS and gin=302.9±100.4pS, 
n=8)  primary airway epithelial cells. The reversal 
potentials were Erev=-22.4±3.9mV and Erev=-
22.4±1.9mV in the non-CF and CF cells, 
respectively, indicating that Cl
-
 ions (ECl -39mV) 
were the main charge carrier under these 
conditions (see table 1). 
LXA4 (100nM) exposure stimulated the 
whole-cell currents in NHBE and CFBE cells, in a 
time-dependent manner, as illustrated in figure 3.  
In the non-CF NHBE primary cultures, LXA4 
enhanced the basal outward conductance by 
4.12±0.17 fold (n=13), and the inward 
conductance by 2.98±0.15 fold (n=13), without 
producing a significant change in the reversal 
potential (Erev=-21.4±5.8 mV). LXA4 also 
stimulated the whole-cell current in CF bronchial 
cells (figure 3B). LXA4 increased the outward 
conductance in CFBE cells by 3.97±0.19 fold 
(n=8) and the inward conductance by 3.57±0.19 
fold (n=8) without affecting the reversal potential 
(Erev=-23.8±3.1mV). The maximum stimulatory 
effect on membrane conductance in NHBE cells  
was obtained after 10 min exposure to LXA4  and  
declined thereafter to control levels (figure 3A).  
In CF airway epithelial cells, the increased 
membrane current and conductance changes 
induced by LXA4 were sustained without recovery 
to basal values over the 15 min period of 
observation (figure 3B). The inward conductance 
(for outward flux of Cl
-
 from the cell) was 
significantly increased by LXA4 in all cell types 
studied including primary cultures of CF and non-
CF bronchial epithelia and in the CF and non-CF 
cell lines (figure 3C). 
The stimulatory effect of LXA4 on 
membrane current and conductance in non-CF 
NuLi-1 cells (figure 4A) and CF CuFi-3 cells 
(figure 4B) was found to be dose-dependent with 
significant responses observed at concentrations 
as low as 1pM and the maximum response 
achieved at 10nM lipoxin (figure 4C).  
 
Role of the ALX/FPR2 receptor in the 
membrane  current and conductance responses 
to LXA4. We have tested the effect of the  
ALX /FPR2 receptor antagonist Boc-2 on the 
whole-cell current and conductance response to 
100nM LXA4 treatment in NuLi-1 cells (figure 
5A) and CuFi-3 cells (figure 5B). Treatment of 
these cells withBoc-2 (10µM) for 1h completely 
abolished the effect of LXA4 on the whole-cell 
current (figure 5A, 5B) and inward conductance 
(Figure 5C). 
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LXA4 effect on Cl
-
 secretion. To investigate 
the contribution of Cl
-
 currents to the LXA4 
induced current, we tested the effects of NPPB 
(calcium-activated Cl
-
 channel inhibitor) and 
CFTR-inh172 (CFTR Cl
-
 channel inhibitor), on 
membrane current and conductance responses to 
LXA4 in CF and non-CF cells (figure 6). The 
addition of NPPB (1μM) cells 10 min after 
exposure to LXA4 (100nM), immediately 
inhibited the whole-cell current by 103.59± 17.47 
% in non- CF primary cultures (n=4) and by 
76.19± 4.12 % in CF primary cultures (n=3). A 
typical experiment in NHBE cells is shown in 
figure 6A. Pre-treatment of  CFBE primary 
cultured cells for 2 min with NPPB (1μM) prior to 
LXA4 exposure, completely inhibited the 
stimulatory effect of LXA4 on whole-cell current 
(p>0.5, n=3). In addition, when equimolar Cl
-
 was 
used in the bath and patch pipette, LXA4 did not 
stimulate whole-cell current in any of the cell 
types tested (data not shown). NBBP also 
inhibited the LXA4-stimulated membrane inward 
conductance in CF and non-CF cells. A summary 
of the inhibitory effects of NPPB on inward 
conductance in the CFBE and non-CF primary 
cultured cells, and the CuFi-3 cell line are 
presented in figure 6A. 
The specific CFTR inhibitor, CFTR-inh172, 
did not affect the stimulation of the whole-cell 
current by LXA4 in non-CF NuLi-1 cells (figure 6 
B). There was no effect of CFTR-inh172 on basal 
or LXA4-stimulated membrane current and 
conductance in CFBE and CuFi-3 cells (data not 
shown), consistent with the absence of functional 
CFTR. When Nuli-1 cells were pre-treated with 
CFTR-inh172 (5mM), subsequent LXA4 exposure 
stimulated the outward and inward conductances 
by 2.1±0.15 fold and 2.5±0.14 fold (n=3), 
respectively (figure 6B). These results indicate 
that the stimulatory effect of LXA4 on whole-cell 
current and conductance in non-CF and CF 
bronchial cells is mainly due to activation of 
NPPB-sensitive Cl
-
 channels and does not involve 
CFTR channels.  
 
Role of intracellular Ca
2+
 in the whole-cell 
current responses to LXA4. In order to evaluate 
the role of intracellular Ca
2+
 in the LXA4 induced 
whole-cell currents, we used BAPTA-AM as a 
chelator of intracellular Ca
2+
. Cells were bathed in 
Kreb’s solution and the patch pipette contained 
100nM Ca
2+
 with 5mM  EGTA and 10μM 
BAPTA-AM. Under these conditions of low 
intracellular Ca
2+
 (~1pM , estimated from free 
software WEBMAXC 
http://www.stanford.edu/~cpatton/webmaxc/web
maxcS.htm ),  the stimulatory effect of LXA4 on 
whole-current was abolished in NuLi-1 cells 
(figure 7A) and in CuFi-3 cells (figure 7B).. 
Furthermore, BAPTA-AM pre-treatment 
completely abolished the effect of LXA4 on the 
membrane inward conductance in these cells 
(Figure 7C).  
 
LXA4 effects on Airway Surface Liquid 
Height. The consequence of  LXA4 stimulation of 
whole-cell Cl
-
 currents and transepithelial Cl
- 
secretion on ASL height was investigated in  
NuLi-1, CuFi-1 and CuFi-3 epithelial monolayers. 
The ASL measurements were carried out on the 
monolayers after a period of 24 hours exposure to 
an air-liquid interface to allow fluid 
absorption/secretion and ASL height to reach a 
steady state.  LXA4 (100nM) was applied to the 
epithelium from the basolateral compartment of 
the chamber 15 minutes prior to ASL 
measurements. Under control conditions (without 
LXA4 and 24h after a steady-state ASL height was 
established), the non-CF NuLi-1 cell monolayers 
showed a continuous unbroken ASL layer (figure 
8A) and a mean ASL height of 7.2±0.1µm (n=3), 
whereas CF cell monolayers presented a disrupted 
and thinner ASL layer of 4.6±0.1µm in CuFi-1 
cells (n=6, p<0.005) and of 6.2±0.1µm in CuFi-3 
cells (n=4, p<0.005) (figure 8A). 
 
Exposure to LXA4 (100nM) significantly 
increased the ASL height in both non-CF and CF 
cell monolayers (figure 8A,B). LXA4 treatment 
produced a maximum ASL height increase from 
7.2±0.1µm to 10.0±0.2µm in Nuli-1 epithelia 
(n=3),  and from 4.6±0.1µm to 11.1±0.2µm in 
CuFi-1 epithelia (n=6), and from 6.2±0.1µm to 
9.8±0.2µm in CuFi-3 epithelia (n=4) (p<0.001). In 
CF epithelium, the disrupted appearance of the 
ASL layer largely disappeared after LXA4 
treatment (figure 8A).  
 
Role of Cl
-
 transport in the ASL height 
responses to LXA4. In order to investigate the 
contribution of Cl
-
 secretion in the generation of 
the ASL, we used bumetanide to inhibit the 
basolateral Na/K/2Cl co-transporter. Bumetanide 
(1µM) treatment significantly decreased the basal 
ASL height from 7.2±0.1µm to 5.9±0.1μm 
(p<0.001, n=6) in NuLi-1 monolayers but had no 
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significant effect on ASL height in CuFi-1 
epithelia (4.6±0.1µm in control and 4.82±0.1μm 
(p >0.05, n=6) after bumetanide) and in CuFi-3 
epithelia (6.2±0.1µm in control and 6.1±0.1μm (p 
>0.05, n=4) after bumetanide). These data indicate 
that Cl
-
 channels contribute to the generation of 
the basal ASL height in the non-CF epithelium. 
Furthermore, bumetanide (1µM) significantly 
abolished the ASL height increase induced by 
LXA4 in NuLi-1 and CuFi-3 monolayers (figure 
8B). The ASL height measured after LXA4 
exposure in the presence of bumetanide was 
significantly decreased in NuLi-1 (5.7±0.1µm, 
n=3, p<0.05) and in CuFi-1 (4.86±0.1µm, n=6, 
p<0.001) and in CuFi-3 (6.2±0.1µm, n=6, 
p<0.001) compared to LXA4 alone (figure 8B). 
Taken together, these results indicate that the 
stimulatory effect of LXA4 on ASL height mainly 
involves Ca
2+
 -dependent Cl
-
 secretion via NPPB-
sensitive channels in both CF and non-CF 
epithelia. 
 
 Role of the ALX/FPR2 receptor in the 
ASL height responses to LXA4. We tested the 
effect of the ALX/FPR2 receptor antagonist Boc-2  
on the ASL height response to LXA4.  Boc-2 
significantly reduced the effect of LXA4 on ASL 
height in Nuli-1 and CuFi-3 epithelial monolayers 
without affecting the basal ASL height  (figure 
8B). These data, taken together, support the 
conclusion that the ALX/FPR2 receptor mediates 
the effect of LXA4 on ASL height as well as on  
calcium mobilization and  Cl
- 
secretion. 
 
DISCUSSION 
 
In this study, we report the first evidence 
for a novel effect of the endogenous lipoxin LXA4 
to stimulate an increase in Airway Surface Liquid 
height, by enhancing Ca
2+
 activated Cl
-
 transport 
in bronchial epithelial cells obtained from patients 
with CF and non-CF patients and in airway cell 
lines. 
In the healthy lung, the ASL, a thin layer of 
fluid covering the surface of the bronchial 
epithelium allows cilia to beat effectively (15). 
Maintenance of an optimal height of the ASL for 
ciliary beat is crucial for the quality of 
mucociliary clearance (16-19). Epithelial ion 
transport regulates the ASL height, mainly by 
generating osmotic gradients that provide a 
driving force for transepithelial ion and water 
movement (20). In CF, the lack of functional 
CFTR leads to a reduced ASL height, resulting in 
an impaired mucociliary clearance that promotes 
chronic bacterial infection of the airways (3). In a 
previous study, we reported that LXA4 stimulated 
an intracellular Ca
2+
 mobilization in a normal 
human airway epithelial cell line 16HBE14o- (7). 
Here, we tested the hypothesis that LXA4, which 
is reduced in CF airways (4), could induce a Ca
2+
 
signal coupled to an increased Cl
-
 secretion in CF 
epithelium thus providing a compensatory 
mechanism for the absent cAMP-mediated Cl
-
 
transport via mutated CFTR and enhancing airway 
lumen hydration and ASL height. 
Other studies have shown that LXA4 exerts 
biological actions on human airway epithelial 
cells, with a maximal effect observed at 100nM. 
LXA4 (100nM) inhibited IL-8 production by 
airway epithelial cells (21), stimulated an 
intracellular Ca
2+
 increase (7), increased Z0-1 
expression at the plasma-membrane and 
transepithelial electrical resistance (22), and 
enhanced epithelial repair after an acid injury 
(23). We report here, novel effects of  LXA4 on 
ion and fluid transport in normal and CF bronchial 
epithelia. 
Our studies show that LXA4 induces an 
intracellular Ca
2+
 mobilization in normal and CF 
epithelium. This Ca
2+
 response to LXA4 involves 
the ALX/FPR2 receptor, since the FPR2 receptor 
antagonist Boc-2 inhibited the effect. This result 
supports our previous study which suggested that 
the Ca
2+
 signal induced by LXA4 was mediated by 
the ALX/FPR2 receptor since the Ca
2+
 response to 
LXA4 was only obtained in the 16HBE14o- 
airway epithelial cell line that express the receptor 
whereas LXA4 did not produce any Ca
2+
 response 
in the A549 cell line which does not express 
ALX/FPR2 (7).  
 Our results indicate that in non-CF airway 
epithelial cells, LXA4 generates a rapid and 
transient calcium signal mainly due to the release 
of Ca
2+
  from intracellular stores and not by Ca
2+
 
entry since the calcium signal was not affected by 
the removal of external Ca
2+
. This is in accordance 
with our previous report showing that most of the 
Ca
2+
 mobilization  induced by LXA4 was 
generated from thapsigargin sensitive stores (7). 
In contrast, in CF airway epithelial cells, the 
duration of the Ca
2+
 signal induced by LXA4 was 
greater than in non-CF cells. Although, in CF 
cells, the removal of external calcium did not 
affect the maximum peak calcium increase, the 
calcium response to LXA4 became more transient. 
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These results suggest that, in CF airway epithelial 
cells, in addition to the calcium flux from 
intracellular calcium stores, LXA4 also stimulates 
a calcium entry which leads to an overall larger 
calcium mobilisation than in normal airway 
epithelial cells. The observed differences reported 
in the literature between the Ca
2+
 signal obtained 
upon agonist exposure in CF and non-CF airway 
epithelial cells are controversial. Some authors 
reported that expression of either CFTR or 
∆F508CFTR in airway epithelial cells had no 
effect on intracellular Ca
2+
 (24). However, our 
results are in accordance with the demonstration 
that Ca
2+
 signaling is abnormal in CF airway 
epithelial cells and that correction of the abnormal 
trafficking of ∆F508CFTR protein restored 
intracellular Ca
2+
 homeostasis (25). Recent reports 
also indicate that intracellular Ca
2+
 signals 
induced by pro-inflammatory mediators are 
increased in CF airway epithelia compared to non-
CF due to an expansion of the apical ER Ca
2+
 
stores in CF airway epithelial cells (26). This 
finding is coherent with several studies showing 
that the nasal transepithelial electrical potential 
responses to agents that promote an intracellular 
Ca
2+
mobilization and Ca
2+
-dependent Cl
–
 
conductance were higher in CF patients than in 
normal subjects (27-30).  
 Intracellular Ca
2+
 regulates several 
epithelial functions including ion transport, mucin 
secretion, and ciliary beat frequency which 
constitute a primary mode of a non-specific 
cleansing process and lung protection. Our results 
indicate that the Ca
2+
 signal induced by LXA4 is 
coupled to an increased Cl
-
 secretion in CF 
epithelium. LXA4 stimulated the whole-cell 
current and conductance in non-CF and CF 
epithelial cells. The inhibitory effect of BAPTA 
used as a chelator of intracellular Ca
2+
 
demonstrated the role of Ca
2+
 in the stimulation of 
the whole-cell currents by LXA4. The sensitivity 
of basal and stimulated whole-cell currents to 
NPPB or Cl
-
 substitution, underscores the major  
contribution of Cl
- 
secretion to the generation of 
the whole-cell current. These results agree with 
our previous report indicating that LXA4 
stimulated a Ca
2+
 -activated transepithelial Cl
-
 
secretion in non-CF bronchial epithelial cells (7). 
Since we found that LXA4 stimulation of the 
whole-cell currents was present in CF airway 
epithelia (in which CFTR is not functionally 
expressed), LXA4 most probably affects Cl
-
 
channels other than CFTR. In addition, we found 
that the time course of the LXA4 effect on whole-
cell currents was different between non-CF and 
CF cells, with a transient current increase in non-
CF cells compared to CF cells where the current 
increase was more sustained. One explanation 
may be that the time course of the effect of LXA4 
on the Cl
-
 currents is directly related to the time 
course of the intracellular calcium change induced 
by LXA4. Therefore, the greater and sustained 
effect of LXA4 on whole-cell currents in CF cells 
could be related to the long lasting Ca
2+
 signal 
obtained in CF airway epithelial cells. Finally, the 
ineffectiveness of CFTR inh-172 on the LXA4 
stimulation of whole-cell currents indicates that 
the effect of LXA4 on Cl
-
 secretion is not 
mediated by CFTR activation. This conclusion is 
strengthened by the observation that bumetanide 
reduces further the ASL height compared to Boc-2 
treatment in Nuli-1 cells but not in CuFi-3 cells 
where functional CFTR is absent. If LXA4 had 
stimulated CFTR and Ca
2+
-dependent Cl
-
 channels 
we would expect equivalent inhibition of ASL 
height by Boc-2 and bumetanide in Nuli-1 cells. 
Our results show that the stimulatory effect 
of LXA4 on Cl
-
 secretion induces a subsequent 
increase ASL height in both normal and CF 
epithelia. The CF monolayers generate a thinner 
ASL layer than non-CF airway epithelial 
monolayers which correlates with the diminished 
ASL in CF airways reported in the literature (19). 
In addition, we observed that in control 
conditions, the non-CF cell monolayers showed a 
continuous ASL layer whereas in CuFi-1 
monolayers this liquid layer was disrupted. The 
ASL gaps are localised over mucin secreting 
goblet cells and could result from localised de-
hydration and mucus plugging of the ASL. After 
LXA4 exposure in CF cells, the ASL height 
significantly increased with no disruption of the 
ASL layer, suggesting that LXA4 induces 
hydration of the ASL and possibly reduced mucin 
secretion at the apical surface of the epithelium. 
The inhibitory effect of bumetanide indicates that 
the effect of LXA4 on ASL height  is mainly 
dependent on stimulation of transpithelial Cl
-
 
transport. However, we cannot exclude the 
possibility that LXA4 can also exert its action to 
increase ASL height through the inhibition of 
ENaC activity which is known to be down-
regulated by increased intracellular Ca
2+
. Taken 
together, our results provide evidence for a novel 
role of LXA4 in stimulating Ca
2+
 activated Cl
-
 
secretion and ASL generation in CF and non-CF 
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airway epithelium. Thus LXA4 or its stable 
analogues may provide a novel therapeutic 
strategy to rehydrate the CF airway by modulating 
ion transport and airway surface liquid volume via  
pathways which bypass defective CFTR. Our 
results also indicate that the reduced levels of 
LXA4 observed in CF patients may be an 
additional contributory mechanism by which 
mucociliary clearance is altered in CF airways. 
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FIGURE LEGENDS 
 
Figure 1. LXA4 effect on intracellular Ca
2+
 activity in non-CF and CF bronchial epithelial cells. 
(A) Typical effect of LXA4 (100nM) on the cytosolic Ca
2+
 (ratio F340/F380) measured in Nuli-1 and 
CuFi-3 cell lines and in normal and CF primary cultures of bronchial epithelial cells (NHBE and 
CFBE) in control (plain line) and in external Ca
2+
 -free conditions (dotted line). (B) Mean values of 
the maximum increase in Ca
2+
 in non-CF (Nuli-1 and NHBE) and in CF (CuFi-1, CuFi-3, CuFi-4 cell 
lines and CFBE) bronchial epithelial cells. (* denotes: p<0.05, ** denotes: p<0.01). 
 
Figure 2. Effect of Boc-2 on the intracellular Ca
2+
 signal induced by LXA4. (A)Typical effect of 
LXA4 (100nM) and ATP (100μM) on cytosolic Ca
2+
 (ratio F340/F380) in NuLi-1 cells in control 
conditions (upper panel) and after 24 hours of pre-treatment with Boc-2 (10μM) a specific inhibitor of 
ALX/FPR2 (lower panel). (B) Mean values corresponding (* denotes: p<0.05, ** denotes: p<0.01). 
 
Figure 3. Time dependency of the effect of LXA4 on the whole-cell currents in normal (NHBE) 
and CF (CFHBE) bronchial epithelial cells in primary culture.  
Typical I-V relationships and corresponding current records obtained before and after 5, 10 and 15 min 
exposure to LXA4 (100nM) in NHBE (A) and CFHBE (B) isolated bronchial epithelial cells in 
primary culture. (C) Bar charts representing averages of the inward conductances (pS) in NHBE and 
in CFHBE bronchial epithelial cells. Mean Mean inward conductance changes normalized to control 
values (gi/gic) obtained in control conditions (open bars) and 10 min after LXA4 (100nM) exposure 
(black bars). 
 
Figure 4. Dose dependency of the effect of LXA4 on the whole-cell currents of normal (Nuli-1) 
and CF (CuFi-3) bronchial epithelial cell lines.  
Typical I-V relationships and corresponding current records obtained before and after 10 min exposure 
to 1pM, 1nM, 10nM and 100nM  LXA4 in Nuli-1 (A) and CuFi-3 (B) cell lines. (C) Mean inward 
conductance changes normalized to control values(gi / gic obtained without LXA4) as a function of 
LXA4 concentration in Nuli-1 (open bars) and CuFi-3 (black bars) cells. 
 
Figure 5. Effect of Boc-2 on the whole-cell currents stimulated by LXA4 in normal (Nuli-1) and 
CF (CuFi-3) bronchial epithelial cell lines.  
Typical I-V relationships and corresponding current records obtained in control condition, with Boc-2 
(10μM)  and Boc-2 with LXA4 (10min, 100nM) in Nuli-1 (A) and CuFi-3 (B) isolated cells. (C) Mean 
inward conductance changes normalized to control values(gi/gic) obtained upon exposure to LXA4 
alone (10min, 100nM)  and after Boc-2 pretreatment in Nuli1 (open bars) and CuFi-3 (black bars) 
cells. 
 
Figure 6. Effects of Cl
-
 channel inhibitors on the whole-cell currents stimulated by LXA4.  
(A). Typical I-V relationship of the effect of NPPB (1μM) after the stimulation of primary cultures of 
bronchial epithelial cells with LXA4 (100nM). Histogram of the inhibitory effect of NPPB on the 
inward currents obtained in non-CF primary NHBE cells., CuFi-3 cells and CF primaryCFHBE cells 
after stimulation with LXA4 (100nM).  
(B). Typical I-V current relationships of the effect of LXA4 (100nM) obtained in NuLi-1 cells after 
treatment with the CFTR channel inhibition CFTR-inh172 (5mM) and histogram showing the absence 
of inhibitory effect in Nuli-1 cells.  
 
Figure 7. Effect of BAPTA-AM on the whole-cell currents induced by LXA4.  
Typical I-V current relationships obtained upon exposure to LXA4 (100nM, 10min) with or without 
BAPTA (10µM) treatment 1h prior to LXA4 exposure in NuLi-1 (A) and CuFi-3 (B) cells. (C) Mean 
inward conductance changes normalized to control values (gi/gic) obtained upon exposure to LXA4 
 alone (10min, 100nM)  and after BAPTA-AM pre-treatment in Nuli1 (open bars) and CuFi-3 (black 
bars) cells. 
 
Figure 8. LXA4 (100nM) effects on airway surface liquid height in NuLi-1 and CuFi-3 epithelia. 
(A) Typical z-plane confocal sections of showing ASL responses to LXA4 in NuLi-1 and CuFi-3 
epithelial cell monolayers labelled with calcein green, and  ASL labelled with dextran-conjugated 
Texas red™ fluorochrome. (B) Effect of bumetanide (10µM) and Boc-2 (10μM) on the ASL height 
responses to  LXA4  treatment in NuLi-1 and CuFi-3 epithelial monolayers 
 
  
 
 
  
  
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 Table 1 
 
 
 
  Gout (pS) Gin (pS) Vr (mV) n 
PC Control 612.2±165.2 227.7±99.3 -22.4±3.9 16 
LXA4 1742±147.2 431.18±36.6 -21.4±5.8 13 
CFPC Control 855.4± 192.9 302.9±100.4 -22.4±1.9 8 
LXA4 3187.5±172.1 874.4±43.4 -23.8±3.1 8 
NuLi-1 Control 622.1±168.9 298.7±85.5 -23.8±3.2 8 
LXA4 1365.1±75.8 507.3±24.2 -22.9±3.7 6 
CuFi-3 Control 979.6±146.8 109.6±61.36 -21.7±3.6 5 
LXA4 2156.5±232.7 375.3±132.97 -24.7±4.0 5 
 
Mean outward (Gout) and inward (Gin) conductances and reversal potentials (Vr) measured in non CF 
and CF airway epithelial cells in primary culture and NuLi-1 and CuFi-3 cell lines in control 
conditions and stimulated by LXA4 (100nM, 10 min). 
 
